Drug Discovery Stocks List

Symbol Grade Name % Change
ATHX F Athersys, Inc. -2.73
BLRX C BioLineRx Ltd. -1.71
BMRN F BioMarin Pharmaceutical Inc. -0.12
VYNT F Vyant Bio, Inc. 0.34
CLVS D Clovis Oncology, Inc. -2.45
CRIS B Curis, Inc. -21.39
INFI D Infinity Pharmaceuticals, Inc. -4.79
IONS F Ionis Pharmaceuticals, Inc. 0.79
LXRX D Lexicon Pharmaceuticals, Inc. -3.42
SUPN B Supernus Pharmaceuticals, Inc. 0.78
CRL B Charles River Laboratories International, Inc. 0.41
GE C General Electric Company 1.33
GLW C Corning Incorporated 1.79
HTGC C Hercules Technology Growth Capital, Inc. 3.76
IEX B IDEX Corporation 2.71
PKI A PerkinElmer, Inc. 2.71
WAT B Waters Corporation 3.86
GLYC F GlycoMimetics, Inc. 5.33
BLFS F BioLife Solutions, Inc. -2.70
LRMR F Larimar Therapeutics, Inc. 11.65
BBC F Virtus LifeSci Biotech Clinical Trials ETF -2.39
SMMT C Summit Therapeutics plc -0.37
SRRA A Sierra Oncology, Inc. -6.27
HCM F Hutchison China MediTech Limited 9.66
VTGN B VistaGen Therapeutics, Inc. -6.87
TPVY D TriplePoint Venture Growth BDC Corp. 5.75% Notes due 2022 0.00
NCNA F NuCana plc -8.31
STRO C Sutro Biopharma, Inc. -8.39
TWST F Twist Bioscience Corporation -4.64
MREO D Mereo BioPharma Group plc -9.09
IDYA D IDEAYA Biosciences, Inc. -2.28
BCEL F Atreca, Inc. -9.06
ADPT F Adaptive Biotechnologies Corporation 1.52
BNTX B BioNTech SE -4.16
LMNL D Liminal BioSciences Inc. -1.65
SDGR F Schrodinger, Inc. -1.06
RLAY F Relay Therapeutics, Inc. -1.36
CMPS F COMPASS Pathways Plc -5.94
VGAC F VG Acquisition Corp. / 23andMe 0.61
LIXT D Lixte Biotechnology Holdings, Inc. -4.83
CERT C Certara, Inc. -4.99
PHAR F Pharming Group N.V. 0.00
RXRX D Recursion Pharmaceuticals, Inc. -8.34
View As Page of Charts


Related ETFs - A few ETFs which own one or more of the above listed Drug Discovery stocks.

Recent Signals

Date Stock Signal Type
2021-05-12 ADPT Lower Bollinger Band Walk Weakness
2021-05-12 ATHX 180 Bearish Setup Bearish Swing Setup
2021-05-12 ATHX Lower Bollinger Band Walk Weakness
2021-05-12 ATHX Bollinger Band Squeeze Range Contraction
2021-05-12 ATHX Shooting Star Candlestick Bearish
2021-05-12 BBC 180 Bearish Setup Bearish Swing Setup
2021-05-12 BBC New Downtrend Bearish
2021-05-12 BBC Slingshot Bearish Bearish Swing Setup
2021-05-12 BCEL Lower Bollinger Band Walk Weakness
2021-05-12 BLRX Calm After Storm Range Contraction
2021-05-12 BLRX MACD Bearish Signal Line Cross Bearish
2021-05-12 BLRX Fell Below 50 DMA Bearish
2021-05-12 BLRX Fell Below 20 DMA Bearish
2021-05-12 BLRX Stochastic Reached Oversold Weakness
2021-05-12 BLRX 1,2,3 Pullback Bullish Bullish Swing Setup
2021-05-12 BMRN Lower Bollinger Band Walk Weakness
2021-05-12 BMRN NR7 Range Contraction
2021-05-12 BNTX MACD Bearish Signal Line Cross Bearish
2021-05-12 BNTX Boomer Buy Setup Bullish Swing Setup
2021-05-12 CERT Stochastic Reached Oversold Weakness
2021-05-12 CERT MACD Bearish Centerline Cross Bearish
2021-05-12 CLVS Slingshot Bearish Bearish Swing Setup
2021-05-12 CLVS Bollinger Band Squeeze Range Contraction
2021-05-12 CLVS 200 DMA Resistance Bearish
2021-05-12 CLVS 20 DMA Resistance Bearish
2021-05-12 CMPS Fell Below 20 DMA Bearish
2021-05-12 CMPS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-12 CMPS 180 Bearish Setup Bearish Swing Setup
2021-05-12 CRIS MACD Bullish Signal Line Cross Bullish
2021-05-12 CRIS Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-12 CRIS Expansion Pivot Buy Setup Bullish Swing Setup
2021-05-12 CRIS Parabolic Rise Strength
2021-05-12 CRIS Volume Surge Other
2021-05-12 CRIS New 52 Week High Strength
2021-05-12 CRIS Crossed Above 50 DMA Bullish
2021-05-12 CRIS Crossed Above 20 DMA Bullish
2021-05-12 CRIS Pocket Pivot Bullish Swing Setup
2021-05-12 CRIS Wide Range Bar Range Expansion
2021-05-12 CRIS New 52 Week Closing High Bullish
2021-05-12 CRIS New Uptrend Bullish
2021-05-12 CRIS Reversal New Highs Setup Bullish Swing Setup
2021-05-12 CRIS Expansion Breakout Bullish Swing Setup
2021-05-12 CRIS MACD Bullish Centerline Cross Bullish
2021-05-12 CRL New Uptrend Bullish
2021-05-12 CRL 20 DMA Resistance Bearish
2021-05-12 CRL Doji - Bullish? Reversal
2021-05-12 CRL 1,2,3 Pullback Bullish Bullish Swing Setup
2021-05-12 CRL Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-12 GE Bollinger Band Squeeze Range Contraction
2021-05-12 GE Cup with Handle Other
2021-05-12 GE Expansion Pivot Sell Setup Bearish Swing Setup
2021-05-12 GLW Fell Below 50 DMA Bearish
2021-05-12 GLW 180 Bearish Setup Bearish Swing Setup
2021-05-12 GLW Expansion Pivot Sell Setup Bearish Swing Setup
2021-05-12 GLYC Lower Bollinger Band Walk Weakness
2021-05-12 HCM Expansion Breakdown Bearish Swing Setup
2021-05-12 HCM Lower Bollinger Band Walk Weakness
2021-05-12 HTGC Expansion Pivot Sell Setup Bearish Swing Setup
2021-05-12 HTGC Wide Range Bar Range Expansion
2021-05-12 HTGC Fell Below 50 DMA Bearish
2021-05-12 IDYA Fell Below 20 DMA Bearish
2021-05-12 IDYA 180 Bearish Setup Bearish Swing Setup
2021-05-12 IEX Stochastic Reached Oversold Weakness
2021-05-12 IEX Fell Below 20 DMA Bearish
2021-05-12 INFI NR7 Range Contraction
2021-05-12 INFI 180 Bearish Setup Bearish Swing Setup
2021-05-12 IONS Slingshot Bearish Bearish Swing Setup
2021-05-12 IONS Lower Bollinger Band Walk Weakness
2021-05-12 IONS Calm After Storm Range Contraction
2021-05-12 LIXT Narrow Range Bar Range Contraction
2021-05-12 LIXT NR7 Range Contraction
2021-05-12 LMNL 50 DMA Resistance Bearish
2021-05-12 LRMR New 52 Week Low Weakness
2021-05-12 LRMR Wide Range Bar Range Expansion
2021-05-12 LRMR Pocket Pivot Bullish Swing Setup
2021-05-12 LRMR Volume Surge Other
2021-05-12 LXRX NR7 Range Contraction
2021-05-12 LXRX Lower Bollinger Band Walk Weakness
2021-05-12 NCNA Lower Bollinger Band Walk Weakness
2021-05-12 NCNA New 52 Week Low Weakness
2021-05-12 NCNA New 52 Week Closing Low Bearish
2021-05-12 PHAR 50 DMA Resistance Bearish
2021-05-12 PHAR Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-12 PHAR Fell Below 20 DMA Bearish
2021-05-12 PKI NR7 Range Contraction
2021-05-12 PKI Upper Bollinger Band Walk Strength
2021-05-12 RLAY Lower Bollinger Band Walk Weakness
2021-05-12 RLAY New Downtrend Bearish
2021-05-12 RLAY New 52 Week Closing Low Bearish
2021-05-12 RXRX New 52 Week Closing Low Bearish
2021-05-12 SDGR New Downtrend Bearish
2021-05-12 SDGR Jack-in-the-Box Bearish Bearish Swing Setup
2021-05-12 SDGR Lower Bollinger Band Walk Weakness
2021-05-12 SMMT Stochastic Reached Oversold Weakness
2021-05-12 SRRA Pocket Pivot Bullish Swing Setup
2021-05-12 SRRA Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-12 SRRA Upper Bollinger Band Walk Strength
2021-05-12 STRO 50 DMA Resistance Bearish
2021-05-12 STRO Shooting Star Candlestick Bearish
2021-05-12 STRO Bollinger Band Squeeze Range Contraction
2021-05-12 STRO Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-12 STRO 20 DMA Support Bullish
2021-05-12 TWST 180 Bearish Setup Bearish Swing Setup
2021-05-12 TWST Lower Bollinger Band Walk Weakness
2021-05-12 VGAC Stochastic Reached Oversold Weakness
2021-05-12 VGAC Lower Bollinger Band Walk Weakness
2021-05-12 VGAC New 52 Week Closing Low Bearish
2021-05-12 VTGN Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-12 VTGN 20 DMA Support Bullish
2021-05-12 VYNT 180 Bearish Setup Bearish Swing Setup
2021-05-12 VYNT NR7 Range Contraction
2021-05-12 WAT Fell Below 20 DMA Bearish
2021-05-12 WAT MACD Bearish Signal Line Cross Bearish

Recent News for Drug Discovery Stocks

Date Stock Title
May 13 CRIS Impressive Data for Cancer Drug Gives Curis Stock More Room to Run
May 13 BNTX UK Study Answers Question If Two Doses Of COVID-19 Vaccines Can Be Mix-Matched?
May 13 BNTX Scientists are skeptical over the need for COVID-19 booster shots
May 13 CRIS Curis Stock Is On A Wild Ride — What Spooked Investors After A 65% Surge
May 13 GLYC 2 “Strong Buy” Penny Stocks That Could See Outsized Gains
May 13 BNTX Global tally of COVID-19 cases tops 160 million as U.S. gears up to vaccinate 12- to 15-year-olds
May 13 BNTX What the Yankees COVID-19 outbreak proves: no vaccine is 100% effective
May 13 IEX IDEX (IEX) Announces 8% Hike in Quarterly Dividend Rate
May 13 GE General Electric, Raytheon Technologies, and the $7 Billion Race
May 13 PKI PerkinElmer Expands Into Cell Biology With $260M Nexcelom Bioscience Acquisition
May 13 PKI PerkinElmer To Acquire Nexcelom Bioscience For $260M
May 13 BCEL Atreca EPS misses by $0.05
May 13 CERT Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies
May 13 VYNT Vyant Bio Announces Investor Conference Call and Webcast for First Quarter 2021
May 13 BCEL Atreca Reports First Quarter 2021 Financial Results and Recent Corporate Developments
May 13 CMPS COMPASS Pathways ADS reports Q1 results
May 13 CMPS COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
May 13 BNTX Mixing Pfizer and AstraZeneca Vaccines Increases Mild Side Effects but Is Safe, Study Shows
May 13 BNTX CDC Panel Backs Using Pfizer-BioNTech COVID-19 Vaccine For 12-15 Age Group
May 13 BNTX Mixing Pfizer and AstraZeneca COVID-19 vaccines increases mild side effects but is safe, study shows

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as
classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy.
Modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design. Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees). Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity was about US$1.8 billion. Drug discovery is done by pharmaceutical companies, with research assistance from universities. The "final product" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II and III clinical trials, and most of them fail. Small companies have a critical role, often then selling the rights to larger companies that have the resources to run the clinical trials.
Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances.

More about Drug Discovery
Browse All Tags